Business Context and Reporting Period
This Form 8-K reports on the results of a Special Meeting of Stockholders held by Moleculin Biotech, Inc. on February 5, 2026. The record date for the meeting was December 11, 2025, with 2,693,531 shares of common stock outstanding and entitled to vote. A quorum was established with 1,196,312 shares present in person or by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Three proposals were submitted to stockholders with the following outcomes:
- Proposal 1 (Nasdaq Warrant Approval): Approved. Stockholders voted to approve the issuance of up to 2,610,823 shares of common stock upon the exercise of warrants issued on December 11, 2025.
- Votes For: 578,385
- Votes Against: 68,176
- Abstain: 3,444
- Broker Non-Votes: 546,307
- Proposal 2 (Name Change): Not Approved. The proposal to amend the Certificate of Incorporation to change the company name from "Moleculin Biotech, Inc." to "Moleculin Inc." failed. The vote required a majority of outstanding shares to vote "For," which was not achieved.
- Votes For: 1,124,921
- Votes Against: 67,441
- Abstain: 3,950
- Broker Non-Votes: N/A
- Proposal 3 (Adjournment): Approved. Stockholders approved an adjournment if necessary to solicit additional proxies for the Nasdaq Proposal or the Name Change Proposal.
- Votes For: 582,534
- Votes Against: 64,190
- Abstain: 3,281
- Broker Non-Votes: 546,307
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the context of the voting results. The failure of the name change proposal indicates a lack of sufficient shareholder support for that specific corporate action, while the approval of the adjournment suggests the company may continue efforts to secure votes for the failed proposal.
Investor Verification Checklist
- Verify the definitive proxy statement filed on January 2, 2026, for detailed descriptions of the warrant terms and the rationale for the name change.
- Confirm the specific conditions under which the 2,610,823 warrant shares may be issued following the approval of Proposal 1.
- Monitor future filings for any adjourned meetings or additional proxy solicitations related to the failed name change proposal.
- Review the company's capital structure to understand the potential dilution impact of the approved warrant issuance.